Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.35 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.35 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.35 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30705746 | 0.87 | TRPA1 (0.59) | ALDH1A1TRPA1TSHRCYP3A4TDP1 | |
| Benzyl Bromide SCHEMBL1043932 | 0.85 | TSHR (0.70) | ALDH1A1TRPA1TSHRCYP3A4TDP1 | |
| SCHEMBL5972755 | 0.82 | TDP1 (0.46) | ALDH1A1TRPA1TSHRCYP3A4TDP1 | |
| SCHEMBL275339 | 0.82 | ALDH1A1 (0.52) | ALDH1A1TRPA1TSHRCYP3A4TDP1 | |
| SCHEMBL10426400 | 0.82 | ALDH1A1 (0.52) | ALDH1A1TRPA1TSHRCYP3A4TDP1 | |
| SCHEMBL18702923 | 0.80 | CYP3A4 (0.67) | ALDH1A1TSHRCYP3A4TDP1ESR1 | |
| SCHEMBL10874458 | 0.80 | CYP3A4 (0.67) | ALDH1A1TSHRCYP3A4TDP1ESR1 | |
| SCHEMBL2543676 | 0.80 | CYP3A4 (0.67) | ALDH1A1TSHRCYP3A4TDP1ESR1 | |
| SCHEMBL2646943 | 0.80 | TSHR (0.50) | ALDH1A1TRPA1TSHRCYP3A4TDP1 | |
| SCHEMBL376692 | 0.80 | CYP3A4 (0.48) | ALDH1A1CYP3A4TDP1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3687538-B1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | MONTREAL HEART INST (CA) | 2024-04-17 | — | — | EP | disclosed |
| US-11931348-B2 | Methods of treating elevated plasma cholesterol | Montréal Heart Institute (CA) | 2024-03-19 | — | — | US | disclosed |
| US-20230088095-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | Montréal Heart Institute (CA) | 2023-03-23 | — | — | US | disclosed |
| US-11530186-B2 | Inhibitors for the β-catenin / T-cell factor protein-protein interaction | H. Lee Moffitt Cancer Center and Research Center Institute, Inc. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11400082-B2 | Methods of treating elevated plasma cholesterol | Montréal Heart Institute (CA) | 2022-08-02 | — | — | US | disclosed |
| US-20210369688-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | MONTREAL HEART INSTITUTE (CA) | 2021-12-02 | — | — | US | disclosed |
| US-20210017139-A1 | INHIBITORS FOR THE B-CATENIN / T-CELL FACTOR PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-01-21 | — | — | US | disclosed |
| EP-3687538-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | Montreal Heart Institute (CA) | 2020-08-05 | — | — | EP | disclosed |
| WO-2019191410-A1 | INHIBITORS FOR THE Β-CATENIN / T-CELL FACTOR PROTEIN–PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| US-8742123-B2 | HIV integrase inhibitors from pyridoxine | TAIMED BIOLOGICS, INC. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-6180679-B1 | PARASITICIDE | ELI LILLY AND COMPANY | 2001-01-30 | — | — | US | disclosed |
| EP-0934065-A4 | PHARMACEUTICAL COMPOUNDS | LILLY CO ELI (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-0934065-A1 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998046193-A2 | SYNERGISTIC METHOD FOR TREATING A NEOPLASM | ELI LILLY AND COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998046581-A1 | SYNERGISTIC METHOD FOR TREATING CANCER | ELI LILLY AND COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998046221-A1 | METHOD FOR TREATING FUNGAL INFECTIONS | ELI LILLY AND COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| EP-0870506-A1 | Compositions comprising a cryptophycin compound in combination with a synchronizing or activating agent for treating cancer | ELI LILLY AND COMPANY (US) | 1998-10-14 | — | — | EP | disclosed |
| EP-0870501-A1 | Use of specific cryptophycin derivatives for the manufacture of a medicament in the treatment of fungal infections | ELI LILLY AND COMPANY (US) | 1998-10-14 | — | — | EP | disclosed |
| EP-0870510-A2 | Synergistic combination comprising cryptophycin derivatives and microtubule synergizing agents | ELI LILLY AND COMPANY (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1998008505-A1 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017139-A1 | INHIBITORS FOR THE B-CATENIN / T-CELL FACTOR PROTEIN-PROTEIN INTERACTION | CTNNBL1, CTNNB1, APC | ALDH1A1 4313/4885TRPA1 4253/4885TSHR 4294/4885 |
| US-11530186-B2 | Inhibitors for the β-catenin / T-cell factor protein-protein interaction | CTNNB1, CTNNBL1, APC | ALDH1A1 4184/4885TRPA1 4201/4885TSHR 4378/4885 |
| US-20210369688-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | CETP, LDLR, APOB | ALDH1A1 568/4885TRPA1 4204/4885TSHR 994/4885 |
| US-11931348-B2 | Methods of treating elevated plasma cholesterol | CETP, LDLR, APOB | ALDH1A1 568/4885TRPA1 4204/4885TSHR 994/4885 |
| US-20230088095-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | CETP, LDLR, APOB | ALDH1A1 568/4885TRPA1 4204/4885TSHR 994/4885 |
| US-11400082-B2 | Methods of treating elevated plasma cholesterol | CETP, LDLR, APOB | ALDH1A1 568/4885TRPA1 4204/4885TSHR 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.